Cogstate Reports Record Growth and Expands Market Reach

Cogstate Ltd ( (AU:CGS) ) just unveiled an update.

Cogstate Ltd has reported a significant increase in demand for its services, driven by growth in the R&D market for central nervous system diseases and an expansion of its customer base. The company achieved its second-highest quarterly sales contracts in history, with a notable diversification in the indications for these contracts. Despite the increase in operational costs due to growth initiatives, Cogstate expects revenue for the first half of 2026 to improve by 18-20% compared to the previous year. The company is investing in additional resources and technology to support its expansion, although this may slightly impact margins.

The most recent analyst rating on (AU:CGS) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.

More about Cogstate Ltd

Cogstate Ltd is a neuroscience technology company that specializes in optimizing brain health assessments to advance the development of new medicines and enable earlier clinical insights in healthcare. The company provides rapid, reliable, and highly sensitive computerized cognitive tests and supports partners with electronic clinical outcome assessment solutions. Cogstate’s clinical trials solutions include quality assurance services, advanced analytics, and scientific consulting, serving biopharmaceutical companies, academic institutions, and healthcare providers globally.

Average Trading Volume: 181,386

Technical Sentiment Signal: Buy

Current Market Cap: A$410.9M

See more insights into CGS stock on TipRanks’ Stock Analysis page.